Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nan Cheng

Showing results (521-530 of 557) with videos related to

Pageof 56
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 10, 2018
Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy IndividualsFateh Bazerbachi, Samir Haffar, Zhen Wang, et al.
Nucleic Acids Research|November 11, 2017
miRTarBase update 2018: a resource for experimentally validated microRNA-target interactionsChih-Hung Chou, Sirjana Shrestha, Chi-Dung Yang, et al.
Translational Neurodegeneration|February 16, 2021
Recommendations for the diagnosis and treatment of paroxysmal kinesigenic dyskinesia: an expert consensus in ChinaLi Cao, Xiaojun Huang, Ning Wang, et al.
Hepatology International|August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
American Journal of Cancer Research|August 15, 2022
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort studyHung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, et al.
Pageof 56

Showing results (521-530 of 557) with videos related to

Sort By:
Pageof 56
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 10, 2018
Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy IndividualsFateh Bazerbachi, Samir Haffar, Zhen Wang, et al.
Nucleic Acids Research|November 11, 2017
miRTarBase update 2018: a resource for experimentally validated microRNA-target interactionsChih-Hung Chou, Sirjana Shrestha, Chi-Dung Yang, et al.
Translational Neurodegeneration|February 16, 2021
Recommendations for the diagnosis and treatment of paroxysmal kinesigenic dyskinesia: an expert consensus in ChinaLi Cao, Xiaojun Huang, Ning Wang, et al.
Hepatology International|August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
American Journal of Cancer Research|August 15, 2022
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort studyHung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, et al.
Pageof 56